Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemase
- PMID: 23859203
- DOI: 10.4155/fmc.13.94
Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemase
Abstract
Two independent series of inhibitors of Helicobacter pylori glutamate racemase (MurI) were characterized for their kinetic mechanism, and one was used to generate resistant mutants in vitro. Mutant MurI enzymes from these strains were characterized by structural, genetic, kinetic and biophysical methods. Both inhibitor series, pyrazolopyrimidinediones and benzodiazepines, are uncompetitive with respect to the glutamate substrate, and the resistance mutations were found to act by reducing the affinity of MurI for substrate, thereby reducing the pool of enzyme-substrate complex available for binding inhibitor, while still allowing sufficient glutamate racemase activity for peptidoglycan construction. Uncompetitive inhibitors of a single-substrate, single-product enzyme are rare, and this work gives insight into an remarkable resistance mechanism. This article will discuss the projected clinical impact of H. pylori MurI resistance on these types of inhibitors.
Similar articles
-
Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI).Antimicrob Agents Chemother. 2009 Aug;53(8):3331-6. doi: 10.1128/AAC.00226-09. Epub 2009 May 11. Antimicrob Agents Chemother. 2009. PMID: 19433553 Free PMC article.
-
Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty.Bioorg Med Chem Lett. 2012 Sep 1;22(17):5600-7. doi: 10.1016/j.bmcl.2012.07.004. Epub 2012 Jul 20. Bioorg Med Chem Lett. 2012. PMID: 22877632
-
Exploitation of structural and regulatory diversity in glutamate racemases.Nature. 2007 Jun 14;447(7146):817-22. doi: 10.1038/nature05689. Nature. 2007. PMID: 17568739
-
Glutamate racemase as a target for drug discovery.Microb Biotechnol. 2008 Sep;1(5):345-60. doi: 10.1111/j.1751-7915.2008.00031.x. Epub 2008 May 11. Microb Biotechnol. 2008. PMID: 21261855 Free PMC article. Review.
-
[Recent topics on important drugs for H. pylori eradication: Amoxicillin (AMPC)].Nihon Rinsho. 2005 Nov;63 Suppl 11:367-71. Nihon Rinsho. 2005. PMID: 16363561 Review. Japanese. No abstract available.
Cited by
-
Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines.Front Microbiol. 2019 Aug 13;10:1796. doi: 10.3389/fmicb.2019.01796. eCollection 2019. Front Microbiol. 2019. PMID: 31456763 Free PMC article. Review.
-
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens.Int J Mol Sci. 2020 Mar 10;21(5):1881. doi: 10.3390/ijms21051881. Int J Mol Sci. 2020. PMID: 32164177 Free PMC article. Review.
-
Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.Antimicrob Agents Chemother. 2015 Apr;59(4):2337-42. doi: 10.1128/AAC.04410-14. Epub 2015 Feb 2. Antimicrob Agents Chemother. 2015. PMID: 25645840 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
